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Steroid hormones are a diverse class of structurally related molecules, derived from cholesterol, that include
androgens, estrogens, progesterone and corticosteroids.They represent an important group of physiologically
active signalling molecules that bind intracellular receptor proteins and regulate genes involved in
developmental, reproductive and metabolic processes.The receptor proteins share structurally and functionally
related ligand binding and DNA-binding domains, but possess distinct N-terminal domains (NTD) of unique
length and amino acids sequence.The NTD contains sequences important for gene regulation, exhibit structure
plasticity and are likely to contribute to the specificity of the steroid hormone/receptor response.
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Introduction
Steroid hormone receptors (SHR) are intracellular proteins
that regulate patterns of gene expression in target tissues
in response to small lipophilic hormones synthesised from
cholesterol.They are important for normal development,
reproductive function and the regulation of metabolism
and salt balance.The receptor proteins have a
well-defined domain organisation and high-resolution
structures are available for the C-terminal ligand binding
domain (LBD), with different agonist and antagonist
ligands bound, and the zinc-finger DNA-binding domain
(DBD) (Figure 1). SHR have been shown to contain two
transactivation functions: one is represented by a
structurally defined hydrophobic groove on the surface
of the LBD, formed by residues from helices 3, 4, 5 and
12 (AF2), while the other maps to the structurally flexible
N-terminal domain (NTD) and is termed AF1 (Figure 1).
The main determinants for transactivation map to NTD
of both the androgen (AR) and glucocorticoid (GR)
receptors (Figure 2A and reviewed in [Lavery and
McEwan, 2005]) and while generally there is little
sequence conservation between the different SHR-NTDs,
in contrast to the DBD and LBD, short regions of similarity
have been observed for the AR and GR. For example, a
four amino acid synergy control motif [Iniguez-Lluhi and
Pearce, 2000], a hydrophobic signature sequence
implicated in transactivation [Betney and McEwan, 2003]
and a 26 amino acid sequence, that is located within the
AF1 domain, that shows 46% amino acid identity between
AR (amino acids 237 to 262) and GR (amino acids 47 to
103) (IJM unpublished observation).The NTD is
potentially involved in multiple protein-protein interactions
[Lavery and McEwan, 2005] and the length of this domain
has been positively correlated with the activity of AF1 for
different members of the nuclear receptor superfamily
[He et al., 2004b].
Figure 1.  Androgen and glucocorticoid receptor domain
organisation. A hypothetical structural model for the full-length AR and
GR based on structural information for the isolated ligand-binding (LBD)
and DNA-binding (DBD) domains is shown. Note: high resolution
structures are available for the isolated LBD and DBD of nearly all SHR,
but no multi-domain structure has yet been reported for a member of the
nuclear receptor superfamily.The LBD consists of 12 α-helices folded in
a three-layer helical sandwich and is linked via a flexible hinge region to
the DBD, which has a characteristic globular fold made up of two
perpendicular α-helices.The NTD is unique to each SHR and has variable
sequence and length [Lavery and McEwan, 2005].The proposed helical
and unfolded conformation for this domain is based in structure predictions
(see below), spectroscopy analysis and site-directed mutagenesis and
proteolytic sensitivity of the AR- and GR-NTD (see text for details).
Androgen receptor-NTD (NR3C4)
Folding and function
The AR-NTD transactivation function is highly modular,
with key sequences mapping to amino acids 101 to 370
and 360 to 485 and termed TAU1 and TAU5, respectively
[Chamberlain et al., 1996; Jenster et al., 1995; Simental
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to 485 (human AR), consisting of most of TAU1 and all
of TAU5, retained about 70% of the activity of the
full-length NTD when measured in yeast cells in vivo [Reid
et al., 2002b] and also activated a reporter gene in vitro,
when fused to a heterologous DBD [Choudhry et al.,
2006; McEwan and Gustafsson, 1997].
Figure 2. Consensus secondary structure and disorder predictions
for AR-NTD and GR-NTD (A) and (B) Consensus secondary structure
[Combet et al., 2000] and disorder predictions (Glob plot: Linding et al.,
2003) for the AR-NTD and GR-NTD, respectively.The location of AF1 is
shown above the secondary structure plot (blue and red bars represent
α-helix and β-strand structure, respectively) for AR and GR. In addition
the four putative helical regions in AR-AF1 are indicated (A, I-IV) and the
location of three helices observed in the GR-AF1 core (B) are highlighted.
The first 25 amino acids of the AR-NTD contain a FxxLF
motif, that forms part of an amphipathic α-helix (residues
21 to 30) and interacts with the AR-LBD (AF2) [He et al.,
2004b; He et al., 2000]. Predictions of disordered
structure suggest this region is globular (Figure 2A) and
recent structural studies comparing the binding of
peptides containing either an FxxLF or an LxxLL motif
revealed that the AR-NTD peptide forms a charge clamp
with glutamic acid 897 in helix 12 and lysine 720 at the
end of helix 3, and the more bulky hydrophobic residues
fit better into the surface pocket of AF2 [He et al., 2004b;
Hur et al., 2004]. In contrast, a LxxLL motif peptide fails
to make hydrogen bond contacts with the glutamic acid
residue in helix 12 and makes fewer hydrophobic contacts
with the surface of the LBD [He et al., 2004b; Hur et al.,
2004]. Interestingly, while other SHR interact with
coactivator proteins via LxxLL motifs, which bind in the
hydrophobic groove of AF2, the AR-LBD preferentially
binds the AR-NTD and coactivators with more bulky
hydrophobic residues in the sequence F/WxxLF/W/Y [He
et al., 2000; Hsu et al., 2003], which may explain the
relatively weak activity observed for AR-AF2.
The AR-AF1 (amino acids 142 to 485) is predicted to be
highly disordered and has limited structure, as revealed
by circular dichroism and fluorescence spectroscopy,
which is lost upon urea-induced unfolding (Figure 2A and
[Reid et al., 2002a]). In contrast, incubation with the
natural organic osmolyte, trimethylamine-N oxide (TMAO),
or the hydrophobic solvent trifluoroethanol (TFE) induces
and/or stabilises a more folded conformation in the AF1
domain.This folding of AF1 is associated with a more
protease resistant conformation and is concomitant with
a significant increase in α-helical content of AR-AF1
(13-16% to 37-40%), at the expense of both non-ordered
and β-structure [Kumar et al., 2004a; Reid et al., 2002a].
Significantly, this more folded helical conformation is
induced upon binding the AR target factor TFIIF, which
in turn appears to create a platform for further
protein-protein interactions [Kumar et al., 2004a; Reid et
al., 2002a].
Mutations affecting the structure-function of the
AR-NTD
We initially predicated four helical segments within
AR-AF1, which could be disrupted under native conditions
by the introduction of proline residues: helix I, amino acids
175 to 201; helix II, 231 to 252; helix III, 341 to 358; and
helix IV, 393 to 411 (Figure 2A: I-IV) [Reid et al., 2002a].
A 14 amino acid sequence in the first of these regions
was previously shown to be important for AF1 activity
and predicated to form an amphipathic α-helix
[Chamberlain et al., 1996]. Recently, residues in this
region were found to act as a docking site for TAB2, a
component of the N-CoR corepressor complex, which
acts as a sensor molecule for androgen, estrogen and
cytokine signalling pathways [Zhu et al., 2006].
When the AR-NTD sequences from at least twelve
different species were compared, three highly conserved
regions were identified: amino acids 1 to 30, 224 to 258
and 500 to 541 [Betney and McEwan, 2003].The second
of these sequences includes helical region II identified in
the AF1 domain (see above and Figure 2A) and mutation
of conserved hydrophobic residues reduced
transactivation activity, but had minimal, if any effect, on
conformation as determined by fluorescence spectroscopy
and limited proteolysis [Betney and McEwan, 2003].
Interestingly, two mutations A234T and E236G, originally
identified in a mouse model for prostate cancer, also map
to this sequence [Han et al., 2005; He et al., 2004a].
Structure predictions suggest no dramatic changes in
secondary structure for the A234T change, but the
possible increase in an adjacent β-strand structure for
the E234G mutation (IJM unpublished observations). In
recent molecular dynamic simulations these mutations
were suggested to stabilize the predicted helical
conformation [Han et al., 2005]. Garabedian and
co-workers reported on a third mutation identified in a
patient with prostate cancer, P340L, which may also have
altered structural properties [Li et al., 2005].This mutation
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Perspective Folding of the AF-1 transactivation domainFigure 3. SHR-NTD: regions of intrinsic structural disorder. The amino acid compositional bias for regions within the SHR-NTD is shown. Small
(Ala, Gly), uncharged hydrophilic (Asn, Gln, Ser, Thr) and proline residues (Green shading); charged residues (Red and Blue shading); and hydrophobic
residues (Yellow shading). Androgen Receptor, amino acids 1 to 558; Glucocorticoid Receptor, amino acids 1 to 420; Progesterone Receptor, amino
acids 1 to 566; Mineralocorticoid Receptor, amino acids 1 to 602; Estrogen Receptor α, amino acids 1 to 184 and β, amino acids 1 to 148. Amino acid
numbering and sequences are for the human receptors.
is predicted to disrupt local secondary structure (IJM
unpublished observations) and to alter folding of α-helices
in the region of amino acids 331 to 355 [Li et al., 2005].
Interestingly, these mutations have been shown to alter
different protein-protein interactions with coregulatory
proteins: A234T and E236G reduced the binding of the
chaperone protein CHIP [He et al., 2004a], while P340L
enhanced the binding of the AR coregulatory protein
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changes were also observed when a double point
mutation was introduced into a six amino acid repeat
sequence in AF1, 
158PSTLSL
163 (serine to alanine).These
changes disrupted binding of TFIIF [Reid et al., 2002b]
and resulted in a more folded conformation for AF1
[Betney and McEwan, 2003].Thus, taken together these
findings describe two classes of mutation in the AR-NTD:
the first have been shown and/or predicted to alter the
conformational flexibility of this domain and receptor
activity, while the second group alter function without
apparently disrupting structure.To date, about a third of
the single point mutations identified in clinical samples of
prostate cancer map to the AR-NTD [Scher et al., 2004].
Overall, the structure-function studies of the AR-NTD/AF1
have emphasised a dynamic interplay between protein
folding and conformation and receptor function, which
may be further modulated by clinically relevant point
mutations.
Glucocorticoid receptor-NTD (NR3C1);
folding and function
The AF1 function of the GR was initially mapped to amino
acids 77 to 262 for the human receptor. Subsequently, a
58 amino acid core function was delineated to amino
acids 187 to 244 (Reviewed in [Lavery and McEwan,
2005]). Mutations altering hydrophobicity or the acidic
character of both the human and rat GR transactivation
domains were found to impair transactivation activity
[Almlof et al., 1998; Almlof et al., 1995; Iniguez-Lluhi et
al., 1997].This suggests that such residues are important
structurally and/or formed surfaces involved in
protein-protein interactions. Recently, a study combining
mutations in the GR AF1 or AF2 domains with gene array
analysis revealed a differential requirement for the NTD
(AF1) and LBD (AF2) transactivation functions [Rogatsky
et al., 2003], emphasising a potential additional level of
selectivity in SHR signalling.
Figure 2B shows the predictions for secondary structure
and regions of disordered structure within the GR-NTD
and suggests significant disorder within the AF1 domain
and the region N-terminal to the DBD. Folding of the
GR-AF1 (amino acids 77 to 262) or AF1 core (amino
acids 187 to 244) domain into a more stable helical
conformation has been observed in the presence of both
the solvent TFE and the natural solute TMAO. Using NMR
spectroscopy, Dahlman-Wright and co-workers originally
described three helical segments within the AF1 core, in
the presence of 40% TFE: amino acids 189 to 200, 216
to 226 and 235 to 241 (Figure 2B and [Dahlman-Wright
et al., 1995]). Introduction of helix-breaking proline
mutations resulted in disruption to both secondary
structure and transactivation potential [Dahlman-Wright
and McEwan, 1996]. A subsequent study by Thompson
and Kumar and co-workers showed changes in tryptophan
fluorescence emission spectra in the presence of TMAO
and upon DNA binding, indicative of structural changes
within the GR-NTD [Baskakov et al., 1999]. Folding of
the NTD was also shown to enhance the binding of the
coregulatory target proteins TBP, CBP and the p160
family member SRC-2 (GRIP1) [Kumar et al., 2001]. More
recently, these authors showed the binding of TBP to
GR-AF1 occurred in vivo and induced a coil to α-helix
transition with concomitant alterations in the chemical
shifts of four glycine residues present in the GR-AF1 core
region in vitro [Copik et al., 2006; Kumar et al., 2004b].
Therefore, similar to the AR, the GR-AF1 appears
structurally flexible and has the propensity to form an
α-helical conformation. In addition to the above studies
on AR and GR, Warnmark et al (2001) found that the
NTD of estrogen receptor (ER) α and β were unstructured
when studied by both NMR and circular dichroism
spectroscopy. Significantly, the ERα, but not ERβ, -NTD
adopted a more structured conformation upon binding
the general transcription factor the TATA-binding protein
[Warnmark et al., 2001].Thus, in spite of the lack of high
resolution structural data, a large body of evidence now
exists underlining an induced structure model for both
the AR and GR AF1 domains upon specific DNA and/or
protein binding.
Natural disordered sequences and the
SHR-NTD
What is the nature of this structural flexibility? The concept
of regions or even whole domains of proteins being
naturally disordered has gained much attention recently
as more evidence accumulates to support the hypothesis
that such sequences are (i) very common in eukaryotic
proteins and (ii) functionally important [Dunker et al.,
2002; Dyson and Wright, 2005]. Intrinsically unstructured
regions have been implicated in molecular recognition
and assembly of protein complexes and as sites of
post-translational modification [Dunker et al., 2002; Dyson
and Wright, 2005].Thus, a consideration of natural
disordered sequences within steroid receptor-NTDs is
highly appropriate given the available structural
information, the function of this domain in multiple
protein-protein interactions and as a target for
post-translational modifications (phosphorylation and
sumoylation) (Reviewed in [Lavery and McEwan, 2005]).
While lacking any significant level of primary sequence
homology, analysis of the amino acid composition of
SHR-NTDs suggests some shared structural properties.
The presence of a high proportion of proline, serine and
glycine residues in the NTDs of steroid receptors
conforms to the amino acid compositional bias associated
with a signature for intrinsic disorder [Dyson and Wright,
2005]. Figure 3 shows an analysis of the primary amino
acid sequence of the NTD for the six major steroid
receptors, with amino acids colour coded depending on
the properties of their side-chains. It is clear there are
large stretches of potentially disordered structure with a
compositional bias towards small (Ala, Gly), uncharged
hydrophilic (Asn, Gln, Ser, Thr) and proline residues
(Green shading). Interspersed are sequences of charged
(Red and Blue shading) and hydrophobic (Yellow shading)
residues, which may represent interaction sites for
protein-protein interactions and/or more structured
regions. A recent analysis [Lavery and McEwan, 2005]
of individual SHR-NTDs using the trained neural network
programme PONDR® and the GlobPlot predictions for
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the view that these domains contain significant levels of
intrinsically disordered structure and is in good general
agreement with the amino acid compositional bias
profiling shown in Figure 3.There is also good general
agreement correlating potential regions of naturally
disordered structure with sequences identified as playing
a role in the control of gene expression for the different
SHR.Thus, structural flexibility is likely to result from the
amino acid compositional bias and underpin the ability of
SHR-NTD to make multiple protein-protein interactions
with the cellular transcription machinery.
Conclusions and future perspectives
Specificity in SHR signalling is exerted at a number of
key steps, notably the binding of hormone and
subsequent recognition and binding to DNA response
elements.While the structural basis of both hormone and
DNA binding specificity are generally well described, the
structural basis for AF1 activity, located in the distinct
NTD, is only now beginning to be revealed. Extensive
analysis of the isolated AR and GR AF1 domains
emphasises the structural plasticity of this domain and
the importance of flexibility for receptor function. An
important question is what is the conformation of the NTD
in the context of the full-length SHR? From the available
experimental evidence two possible models can be
proposed for SHR-NTD structure: in the first the NTD
exists in an equilibrium of essentially non-ordered,
random-coil conformers, while in the second, the NTD
would exhibit limited structural stability consisting of
regions of disorder and variable levels of secondary
structure.The latter is a particularly attractive model, with
the NTD in a flux of partially folded intermediate structures
that collapse into a stable structure upon protein-protein
interactions. In both models it seems likely that the NTD
structure will be stabilised, at least partially by
intramolecular interactions with the DBD and/or LBD.
Indeed, studies with two domain constructs of the AR
[Brodie and McEwan, 2005], GR [Kumar et al., 1999],
progesterone receptor [Bain et al., 2001] and the
full-length ER [Wood et al., 2001] suggest that the
presence of the DBD and/or specific DNA binding leads
to structural changes in the NTD.Therefore, both intra-
and inter-molecular interactions will result in an induction
and/or stabilisation of a more folded, active conformation
in the SHR-NTD. Future analysis will have to consider
whether different conformations are induced in the NTD
depending on DNA response element and/or target
protein binding, and also the role played by
post-translational modifications (i.e. phosphorylation),
which are likely to lead to additional levels of complexity
and potential specificity in SHR action. Furthermore, as
studies have revealed that both active and non-productive
conformations may be stabilised for the AR-NTD, it is
reasonable to propose that folding of SHR-NTD may
serve as a future target for drug discovery for the
treatment of conditions ranging from cancer to
neurodegeneration.
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